Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ADAR1 Capital Management, LLC is named as a reporting person in SEC Form 4 filings. OQRO lists 71 transactions filed with the SEC under this name, the latest on Nov 13, 2026, each linked to the official Form 4.
Disclosures on record
71
Companies involved
5
9 buys, median +2.3 pts vs S&P 500, beat it 6 of 9 times.
Average +4.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Apr 12, 2025 to Aug 3, 2026, measured from the first close after the filing. Past results, not a forecast.
NextcureNXTC
19 disclosures · Jul 2026 – Nov 2026 · 19 bought
Nov 11, 2026Bought~$63Kdisclosed Nov 13
DetailsOfficial recordNov 6, 2026Bought~$19Kdisclosed Nov 9
DetailsNov 5, 2026Bought~$5.2Kdisclosed Nov 9
DetailsOfficial recordOct 23, 2026Bought~$27Kdisclosed Oct 27
DetailsOfficial recordOct 27, 2026Bought~$18K
DetailsOfficial recordOct 26, 2026Bought~$8.4Kdisclosed Oct 27
DetailsOfficial recordJul 30, 2026Bought~$490Kdisclosed Aug 3
DetailsOfficial recordJul 30, 2026Bought~$386Kdisclosed Aug 3
DetailsOfficial recordJul 30, 2026Bought~$249Kdisclosed Aug 3
DetailsOfficial recordJul 31, 2026Bought~$125Kdisclosed Aug 3
DetailsOfficial recordJul 30, 2026Bought~$120Kdisclosed Aug 3
DetailsOfficial recordJul 30, 2026Bought~$100Kdisclosed Aug 3
DetailsOfficial recordJul 30, 2026Bought~$100Kdisclosed Aug 3
DetailsOfficial recordJul 31, 2026Bought~$38Kdisclosed Aug 3
DetailsOfficial recordJul 31, 2026Bought~$16Kdisclosed Aug 3
DetailsOfficial recordJul 27, 2026Bought~$39Kdisclosed Jul 29
DetailsOfficial recordJul 28, 2026Bought~$32Kdisclosed Jul 29
DetailsOfficial recordJul 29, 2026Bought~$8K
DetailsOfficial recordJul 29, 2026Bought~$9.1K
DetailsOfficial recordInmed PharmaceuticalsINM
20 disclosures · May 2026 – Nov 2026 · 20 bought
Nov 5, 2026Bought~$35Kdisclosed Nov 10
DetailsOfficial recordOct 23, 2026Bought~$5disclosed Oct 27
DetailsOfficial recordOct 16, 2026Bought~$1disclosed Oct 20
DetailsOfficial recordOct 19, 2026Bought~$1.4Kdisclosed Oct 20
DetailsOfficial recordOct 14, 2026Bought~$11Kdisclosed Oct 15
DetailsOfficial recordOct 15, 2026Bought~$1.3K
DetailsOfficial recordOct 13, 2026Bought~$750disclosed Oct 15
DetailsOfficial recordOct 6, 2026Bought~$7.4Kdisclosed Oct 8
DetailsOfficial recordOct 8, 2026Bought~$3K
DetailsOfficial recordOct 7, 2026Bought~$4.1Kdisclosed Oct 8
DetailsOfficial recordOct 5, 2026Bought~$24Kdisclosed Oct 6
DetailsOfficial recordOct 1, 2026Bought~$22Kdisclosed Oct 6
DetailsOfficial recordOct 2, 2026Bought~$11Kdisclosed Oct 6
DetailsOfficial recordSep 15, 2026Bought~$70Kdisclosed Sep 17
DetailsOfficial recordSep 14, 2026Bought~$37Kdisclosed Sep 17
DetailsOfficial recordSep 16, 2026Bought~$11Kdisclosed Sep 17
DetailsOfficial recordJul 15, 2026Bought~$1.6Kdisclosed Jul 18
DetailsOfficial recordMay 19, 2026Bought~$312Kdisclosed May 22
DetailsOfficial recordMay 19, 2026Bought~$300Kdisclosed May 22
DetailsOfficial recordMay 19, 2026Bought~$110Kdisclosed May 22
DetailsOfficial recordTenax TherapeuticsTENX
10 disclosures · Aug 2026 – Oct 2026 · 10 bought
Oct 21, 2026Bought~$551K
DetailsOfficial recordOct 19, 2026Bought~$507Kdisclosed Oct 21
DetailsOfficial recordOct 20, 2026Bought~$406Kdisclosed Oct 21
DetailsOfficial recordSep 3, 2026Bought~$1.6Mdisclosed Sep 8
DetailsOfficial recordAug 31, 2026Bought~$723Kdisclosed Sep 2
DetailsOfficial recordSep 2, 2026Bought~$338K
DetailsOfficial recordSep 1, 2026Bought~$322Kdisclosed Sep 2
DetailsOfficial recordAug 21, 2026Bought~$1.27Mdisclosed Aug 24
DetailsOfficial recordAug 20, 2026Bought~$360Kdisclosed Aug 24
DetailsOfficial recordAug 24, 2026Bought~$188K
DetailsOfficial recordRallybioRLYB
14 disclosures · May 2026 · 14 bought
May 19, 2026Bought~$140Kdisclosed May 21
DetailsOfficial recordMay 18, 2026Bought~$84Kdisclosed May 21
DetailsOfficial recordMay 19, 2026Bought~$2.8Kdisclosed May 21
DetailsOfficial recordMay 13, 2026Bought~$1.05Mdisclosed May 16
DetailsOfficial recordMay 13, 2026Bought~$56Kdisclosed May 16
DetailsOfficial recordMay 15, 2026Bought~$2.8Kdisclosed May 16
DetailsOfficial recordMay 15, 2026Bought~$1.4Kdisclosed May 16
DetailsOfficial recordMay 11, 2026Bought~$350Kdisclosed May 14
DetailsOfficial recordMay 11, 2026Bought~$279Kdisclosed May 14
DetailsOfficial recordMay 11, 2026Bought~$71Kdisclosed May 14
DetailsOfficial recordMay 12, 2026Bought~$11Kdisclosed May 14
DetailsOfficial recordMay 4, 2026Bought~$1.63Mdisclosed May 7
DetailsOfficial recordMay 5, 2026Bought~$491Kdisclosed May 7
DetailsOfficial recordMay 4, 2026Bought~$54Kdisclosed May 7
DetailsOfficial recordKeros TherapeuticsKROS
8 disclosures · Apr 2025 – Oct 2025 · 5 bought · 3 sold
Oct 15, 2025Sold~$77.9M
DetailsOfficial recordOct 15, 2025Sold~$13.2M
DetailsOfficial recordOct 15, 2025Sold~$4.52M
DetailsOfficial recordApr 9, 2025Bought~$5.17Mdisclosed Apr 12
DetailsOfficial recordApr 9, 2025Bought~$3.2Mdisclosed Apr 12
DetailsOfficial recordApr 9, 2025Bought~$768Kdisclosed Apr 12
DetailsOfficial recordApr 9, 2025Bought~$174Kdisclosed Apr 12
DetailsOfficial recordApr 9, 2025Bought~$154Kdisclosed Apr 12
DetailsOfficial recordAs of the latest filing on , ADAR1 Capital Management, LLC reported holding 926,352 shares of Rallybio (RLYB), worth about $14.6M at the last close of $16 (Nov 13, 2026), held through a see footnote. Holdings are also on file at Tenax Therapeutics (TENX), Nextcure (NXTC), Inmed Pharmaceuticals (INM); together they are worth about $33M. In the last 12 months, ADAR1 Capital Management, LLC bought $13.3M in 63 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Rallybio RLYB | 926,352 | 926K see footnote | $16 | $14.6M | May 19, 2026 |
| Tenax Therapeutics TENX | 7,447,000 | 7.45M see footnote | $2 | $12.1M | Oct 21, 2026 |
| Nextcure NXTC | 750,289 | 750K see footnote | $6 | $4.8M | Nov 11, 2026 |
| Inmed Pharmaceuticals INM | 98,297 | 98K see footnote | $16 | $1.53M | Nov 5, 2026 |
Is this ADAR1 Capital Management, LLC’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
ADAR1 Capital Management, LLC bought shares on the open market in 2024, 2025 and 2026 across 6 companies. Sales in 1 of the 3 years since 2024.
ADAR1 Capital Management, LLC reported 71 open-market purchases and 3 sales since 2024; purchases in 3 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $13.3M63×63 trades | — |
| 2025 | $9.46M5×5 trades | $95.7M3×3 trades |
| 2024 | $92K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 19, 2026, ADAR1 Capital Management, LLC reported holding 926,352 shares of Rallybio (RLYB), held indirectly. At the last close of $16 on Nov 13, 2026, that is about $14.6M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, ADAR1 Capital Management, LLC reported 63 open-market purchases worth $13.3M, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
ADAR1 Capital Management, LLC bought shares on the open market in 2024, 2025 and 2026 across 6 companies. Sales in 1 of the 3 years since 2024.
In SEC filings since 2024: the latest open-market purchase is from 2026; the latest open-market sale is from 2025.
6 companies: Inmed Pharmaceuticals (INM, 2026), Nextcure (NXTC, 2026), Rallybio (RLYB, 2026), Tenax Therapeutics (TENX, 2026), Keros Therapeutics (KROS, 2025) and others.
ADAR1 Capital Management, LLC reported 20 open-market purchases and 0 sales here, 2026.
ADAR1 Capital Management, LLC reported 19 open-market purchases and 0 sales here, 2026.
ADAR1 Capital Management, LLC reported 14 open-market purchases and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
